{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:11:55Z","timestamp":1790122315397,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["105-2314-B-002-055-MY2"],"award-info":[{"award-number":["105-2314-B-002-055-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.01.090","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T07:34:16Z","timestamp":1581147256000},"page":"2495-2502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study"],"prefix":"10.1016","volume":"38","author":[{"given":"Chia-Hung","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chu","family":"Chie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Arnold","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.090_b0005","unstructured":"Varicella and herpes zoster vaccines: WHO position paper. Word Health Organization; 2014."},{"key":"10.1016\/j.vaccine.2020.01.090_b0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13052-017-0366-8","article-title":"Varicella associated pneumoniae in a pediatric population","volume":"43","author":"Bozzola","year":"2017","journal-title":"Italian J Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1651-2227.2010.01842.x","article-title":"Post-varicella thrombocytopenic purpura","volume":"99","author":"Amir","year":"2010","journal-title":"Acta Paediat (Oslo, Norway: 1992)"},{"key":"10.1016\/j.vaccine.2020.01.090_b0020","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1542\/peds.108.5.e79","article-title":"Severe complications of varicella in previously healthy children in Germany: a 1-year survey","volume":"108","author":"Ziebold","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jinf.2015.06.004","article-title":"Varicella-zoster virus infections of the central nervous system - Prognosis, diagnostics and treatment","volume":"71","author":"Grahn","year":"2015","journal-title":"J Infection"},{"key":"10.1016\/j.vaccine.2020.01.090_b0030","first-page":"e176","article-title":"Chickenpox and stroke in children: case studies and literature review","volume":"103","author":"Reis","year":"2014","journal-title":"Acta Paediatr (Oslo, Norway: 1992)"},{"key":"10.1016\/j.vaccine.2020.01.090_b0035","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.090_b0040","first-page":"1295","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9\u201324 months","volume":"85","author":"Ramkissoon","year":"1995","journal-title":"South African Med J = Suid-Afrikaanse tydskrif vir geneeskunde"},{"key":"10.1016\/j.vaccine.2020.01.090_b0045","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/S0264-410X(02)00245-1","article-title":"A comparison of safety, tolerability and immunogenicity of Oka\/Merck varicella vaccine and VARILRIX in healthy children","volume":"20","author":"Lau","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.090_b0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00006454-200206000-00014","article-title":"Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children","volume":"21","author":"Shinefield","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.01.090_b0055","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/00365540310015719","article-title":"Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age","volume":"35","author":"Parment","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.090_b0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4269\/ajtmh.2004.70.273","article-title":"Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12\u201324 months old","volume":"70","author":"Gatchalian","year":"2004","journal-title":"Am J Tropical Med Hygiene"},{"key":"10.1016\/j.vaccine.2020.01.090_b0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4161\/hv.8269","article-title":"Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: a randomized, double-blind, cross-over study","volume":"5","author":"Ferrera","year":"2009","journal-title":"Human Vacc"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.01.090_b0070","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1086\/522161","article-title":"Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995\u20132005","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.090_b0075","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)\u2013United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2020.01.090_b0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00006454-199912000-00003","article-title":"Postmarketing evaluation of the safety and effectiveness of varicella vaccine","volume":"18","author":"Black","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.01.090_b0085","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1542\/peds.2008-2384","article-title":"Varicella vaccination and ischemic stroke in children: is there an association?","volume":"123","author":"Donahue","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0090","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.vaccine.2018.04.012","article-title":"Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study","volume":"36","author":"MacDonald","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.090_b0095","unstructured":"Ten threats to global health in 2019. The World Health Organization; 2019. https:\/\/www.who.int\/emergencies\/ten-threats-to-global-health-in-2019 [accessed 1 March 2019]."},{"key":"10.1016\/j.vaccine.2020.01.090_b0100","unstructured":"Taiwan Centers for Disease Control, https:\/\/www.cdc.gov.tw\/ [accessed 1 April 2019]."},{"key":"10.1016\/j.vaccine.2020.01.090_b0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.01.090_b0110","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jclinepi.2005.11.012","article-title":"Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations","volume":"59","author":"Glanz","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2020.01.090_b0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"370","author":"Yih","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.090_b0120","first-page":"20994","article-title":"Innovative applications of immunisation registration information systems: example of improved measles control in Taiwan","volume":"19","author":"Liu","year":"2014","journal-title":"Euro surveillance: Bull Europeen sur les maladies transmissibles = Eur Commun Dis Bull"},{"key":"10.1016\/j.vaccine.2020.01.090_b0125","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","article-title":"Nationwide population science: lessons from the Taiwan National health insurance research database","volume":"175","author":"Hsing","year":"2015","journal-title":"JAMA Internal Med"},{"key":"10.1016\/j.vaccine.2020.01.090_b0130","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.01.090_b0135","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: a 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.090_b0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","article-title":"Drug safety data mining with a tree-based scan statistic","volume":"22","author":"Kulldorff","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.01.090_b0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1541-0420.00039","article-title":"A tree-based scan statistic for database disease surveillance","volume":"59","author":"Kulldorff","year":"2003","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0150","unstructured":"Kulldorff M, Maro Judith C. TreeScanTM: a novel data-mining tool for medical product safety surveillance. In: 33rd International conference on pharmacoepidemiology (ICPE) and therapeutic risk management. Montreal, Quebec; 2017."},{"key":"10.1016\/j.vaccine.2020.01.090_b0155","unstructured":"Kulldorff M, Information Management Services Inc. TreeScan\u2122, https:\/\/www.treescan.org\/ [accessed 1 March 2019]."},{"key":"10.1016\/j.vaccine.2020.01.090_b0160","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2020.01.090_b0165","unstructured":"Paddy Farrington YG-W, Musonda Patrick, Hocine Mounia. Self controlled case series method. the Open University. http:\/\/statistics.open.ac.uk\/sccs [accessed 1 March 2019]."},{"key":"10.1016\/j.vaccine.2020.01.090_b0170","unstructured":"CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR: CDC; 2007."},{"key":"10.1016\/j.vaccine.2020.01.090_b0175","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.090_b0180","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.vaccine.2010.12.017","article-title":"The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study","volume":"29","author":"Gwini","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.090_b0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-016-0225-0","article-title":"The use of relative incidence ratios in self-controlled case series studies: an overview","volume":"16","author":"Hawken","year":"2016","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.vaccine.2020.01.090_b0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12879-015-1154-y","article-title":"Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review","volume":"15","author":"Remschmidt","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.090_b0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4054\/DemRes.2009.20.16","article-title":"The decline of son preference and rise of gender indifference in Taiwan since 1990","volume":"20","author":"Lin","year":"2009","journal-title":"Demogr Res"},{"key":"10.1016\/j.vaccine.2020.01.090_b0200","doi-asserted-by":"crossref","first-page":"14043","DOI":"10.3390\/ijerph121114043","article-title":"Ambulatory care visits to pediatricians in Taiwan: a nationwide analysis","volume":"12","author":"Yang","year":"2015","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2020.01.090_b0205","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management","volume":"156","author":"Mantadakis","year":"2010","journal-title":"J Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0210","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0215","first-page":"i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ (Clin Res ed)"},{"key":"10.1016\/j.vaccine.2020.01.090_b0220","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.78.4.723","article-title":"Population-based studies of varicella complications","volume":"78","author":"Guess","year":"1986","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0225","doi-asserted-by":"crossref","first-page":"e20153741","DOI":"10.1542\/peds.2015-3741","article-title":"Global varicella vaccine effectiveness: a meta-analysis","volume":"137","author":"Marin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.01.090_b0230","doi-asserted-by":"crossref","first-page":"17192","DOI":"10.1038\/s41598-018-35451-y","article-title":"Epidemiology of breakthrough varicella after the implementation of a universal varicella vaccination program in Taiwan, 2004\u20132014","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:31:45Z","timestamp":1778679105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20301432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20301432"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.090","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}